NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal (STA)

Mipomersen for the prevention of cardiovascular events due to homozygous familial or severe heterozygous familial hypercholesterolaemia

Provisional matrix of consultees and commentators (pre-referral)

| Consultees | Commentators (no right to submit or appeal) |
|---|--|
| <u>Manufacturers/sponsors</u> Genzyme Therapeutics (mipomersen sodium) <u>Patient/carer groups</u> Action Heart Afiya Trust Black Health Agency Blood Pressure Association British Cardiac Patients Association Counsel and Care Different Strokes Equalities National Council Grown Up Congenital Heart Patients Association Heart Care Partnership (UK) HEART UK Muslim Council of Britain Muslim Health Network Network of Sikh Organisations Neurological Alliance South Asian Health Foundation Specialised Healthcare Alliance Stroke Association | <u>General</u> Board of Community Health Councils in Wales British Cardiovascular Industry Association British National Formulary Care Quality Commission Commissioning Support Appraisals Service Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Alliance NHS Commercial Medicines Unit NHS Confederation Public Health Wales NHS Trust Scottish Medicines Consortium |
| Professional groups British Association for Nursing in Cardiac Care British Association for Service to the Elderly British Association of Stroke Physicians British Cardiovascular Intervention Society (BCIS) | <u>Relevant research groups</u> British Society for Cardiovascular Research Cardiovascular Diseases Specialist Library (CVDSL) Central Cardiac Audit Database Cochrane Heart Group Cochrane Peripheral Vascular Disease Group |

National Institute for Health and Clinical Excellence Provisional matrix for the proposed technology appraisal of mipomersen for the prevention of cardiovascular events due tohomozygous familial or severe heterozygous familial hypercholesterolaemia Issue date: November 2011

| Consultees | Commentators (no right to submit or appeal) |
|--|--|
| British Cardiovascular Society British Geriatrics Society British Heart Foundation British Society for Haematology Diabetes Monitoring Forum National Heart Forum (UK) Primary Care Cardiovascular Society Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Physicians Royal College of Medicine Society for Cardiological Science & Technology Society for Endocrinology Society for Vascular Technology Society of Vascular Nurses United Kingdom Clinical Pharmacy Association Vascular Society MHS Derby City NHS Ealing Welsh Government | Cochrane Stroke Group CORDA European Council for Cardiovascular Research Heart Disease and Diabetes Research Trust MRC Clinical Trials Unit National Institute for Health Research Research Institute for the Care of Older People Wellcome Trust - Cardiovascular Research Initiative Evidence Review Group Evidence Review Group tbc National Institute for Health Research Health Technology Assessment Programme Associated Guideline Groups National Clinical Guidelines Centre Associated Public Health Groups tbc |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Clinical Excellence Provisional matrix for the proposed technology appraisal of mipomersen for the prevention of cardiovascular events due tohomozygous familial or severe heterozygous familial hypercholesterolaemia Issue date: November 2011

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.